Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance.

Turner D, Kondic AG, Anderson KM, Robinson A, Garon EB, Riess JW, Jain L, Mayawala K, Kang J, Ebbinghaus SW, Sinha V, de Alwis DP, Stone JA.

Clin Cancer Res. 2018 Jun 11. pii: clincanres.0415.2018. doi: 10.1158/1078-0432.CCR-18-0415. [Epub ahead of print]

PMID:
29891725
2.

Dose Finding Versus Speed in Seamless Immuno-Oncology Drug Development.

Mayawala K, Tse A, Rubin EH, Jain L, de Alwis DP.

J Clin Pharmacol. 2017 Oct;57 Suppl 10:S143-S145. doi: 10.1002/jcph.1001. No abstract available.

PMID:
28921649
3.

Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma.

Chatterjee MS, Elassaiss-Schaap J, Lindauer A, Turner DC, Sostelly A, Freshwater T, Mayawala K, Ahamadi M, Stone JA, de Greef R, Kondic AG, de Alwis DP.

CPT Pharmacometrics Syst Pharmacol. 2017 Jan;6(1):29-39. doi: 10.1002/psp4.12140. Epub 2016 Nov 29.

4.

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.

Chatterjee M, Turner DC, Felip E, Lena H, Cappuzzo F, Horn L, Garon EB, Hui R, Arkenau HT, Gubens MA, Hellmann MD, Dong D, Li C, Mayawala K, Freshwater T, Ahamadi M, Stone J, Lubiniecki GM, Zhang J, Im E, De Alwis DP, Kondic AG, Fløtten Ø.

Ann Oncol. 2016 Jul;27(7):1291-8. doi: 10.1093/annonc/mdw174. Epub 2016 Apr 26.

5.

Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example.

Sachs JR, Mayawala K, Gadamsetty S, Kang SP, de Alwis DP.

Clin Cancer Res. 2016 Mar 15;22(6):1318-24. doi: 10.1158/1078-0432.CCR-15-1295. Epub 2015 Nov 23. Review.

6.

Dose selection based on physiologically based pharmacokinetic (PBPK) approaches.

Jones HM, Mayawala K, Poulin P.

AAPS J. 2013 Apr;15(2):377-87. doi: 10.1208/s12248-012-9446-2. Epub 2012 Dec 27. Review.

7.

Spatial modeling of dimerization reaction dynamics in the plasma membrane: Monte Carlo vs. continuum differential equations.

Mayawala K, Vlachos DG, Edwards JS.

Biophys Chem. 2006 Jun 1;121(3):194-208. Epub 2006 Feb 28.

PMID:
16504372
8.

Computational modeling reveals molecular details of epidermal growth factor binding.

Mayawala K, Vlachos DG, Edwards JS.

BMC Cell Biol. 2005 Nov 30;6:41.

9.
10.

Time accelerated Monte Carlo simulations of biological networks using the binomial tau-leap method.

Chatterjee A, Mayawala K, Edwards JS, Vlachos DG.

Bioinformatics. 2005 May 1;21(9):2136-7. Epub 2005 Feb 4.

PMID:
15699024
11.

MAPK cascade possesses decoupled controllability of signal amplification and duration.

Mayawala K, Gelmi CA, Edwards JS.

Biophys J. 2004 Nov;87(5):L01-2. Epub 2004 Sep 28.

Supplemental Content

Loading ...
Support Center